CNA
CNA Financial Corporation
CNA trails on the overall score without a compensating advantage in the available component scores.
MS
Morgan Stanley
MS has the edge over CNA overall, supported by stronger modeled upside and stronger fundamentals.
CNA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| N/A | |
| N/A |
CNA's profitability is currently healthy, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CNA.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
CNA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.8x | $37.32 | -23% |
| Fair | 11x | $42.60 | -12% |
| Forward | 11x | $48.29 | — |
| Current | 13x | $48.29 | — |
| Expensive | 15x | $55.76 | +15% |
Historical ranges are pointers, not guarantees.
CNA has the edge over MS in the historical PE scenario, which offers more potential upside but is not a forecast.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS's PE is in its fair range at 15x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
CNA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Decline | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect CNA's revenue to grow, but its earnings and profitability to decline.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
MS has the edge over CNA on the outlook, with more favorable earnings and profitability expectations.
CNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.59 | +21% |
| Q3 2026 | $3.79 | +3.8% |
| Q2 2026 | $4.55 | +42% |
| Q1 2026 | $4.47 | +36% |
| Q4 2025 | $4.69 | +33% |
| Q3 2025 | $3.65 | -24% |
| Q2 2025 | $3.21 | -32% |
| Q1 2025 | $3.28 | -28% |
| Q4 2024 | $3.52 | -21% |
CNA earned $3.79 per share over the past year, up 3.8% from the year before.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over CNA on earnings, with more consistent year-over-year improvement.
CNA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.8B | +0.1% |
| Q2 2026 | $3.8B | +3% |
| Q1 2026 | $3.7B | +1.4% |
| Q4 2025 | $3.8B | +3.8% |
| Q3 2025 | $3.8B | +5.5% |
| Q2 2025 | $3.7B | +5.6% |
| Q1 2025 | $3.6B | +5.3% |
| Q4 2024 | $3.7B | +5.2% |
CNA's revenue has grown year over year for 16 quarters in a row: $3.8B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.2% | -7.2 points |
| Q2 2026 | 11% | +0.4 points |
| Q1 2026 | 7.3% | -2.4 points |
| Q4 2025 | 9.9% | +9.3 points |
| Q3 2025 | 13% | +3.5 points |
| Q2 2025 | 10% | -1.2 points |
| Q1 2025 | 9.6% | -2.8 points |
| Q4 2024 | 0.6% | -13 points |
CNA's operating margin was 6.2% last quarter, down 7.2 points from the same quarter a year ago.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS has the edge over CNA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over CNA on profitability, with a higher operating margin.
CNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $634M | -9.9% |
| Q2 2026 | $629M | +17% |
| Q1 2026 | $380M | -39% |
| Q4 2025 | $542M | -18% |
| Q3 2025 | $704M | -3.6% |
| Q2 2025 | $538M | -9.9% |
| Q1 2025 | $620M | +28% |
| Q4 2024 | $665M | +34% |
CNA has the edge over MS on cash generation, producing positive trailing cash flow while its opponent burns cash.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS's free cash flow was −$58.3B over the past year, against −$3.7B the year before. Free cash flow isn't a meaningful measure for financial services companies like MS.
CNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +300K shares |
| 1 year | -0.1% | -300K shares |
| 3 years | -0.1% | -300K shares |
| 5 years | -0.3% | -700K shares |
| Available history | -0.2% | -500K shares |
CNA has 272M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $36M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $34M |
| Q4 2024 | — |
CNA spent $36M buying back its own shares over the past year, up 5.9% from the year before.
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over CNA on shareholder dilution, with a more favorable share count trend.
CNA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.9x | Healthy |
| Q2 2026 | 1.6x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 2.1x | Moderate |
| Q4 2024 | 2.0x | Healthy |
CNA has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
CNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.0 | Neutral |
| Stochastic | 35.9 | Neutral |
CNA's weekly RSI is 51 (neutral) and its Stochastic is 36 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
CNA PE vs Financial Services Sector
| Metric | CNA | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 2.2% below |
| PE % | 68 | 63 | 5 pts above |
CNA has the edge over MS on valuation relative to its sector.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS is trading at 15x earnings, a 15% premium to the Financial Services sector's median of 13x.
CNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.4 | 1.9% above |
| 20 week MA | $49.3 | 2% below |
| 50 week MA | $47.6 | 1.5% above |
| 100 week MA | $47.4 | 1.9% above |
| 200 week MA | $45.4 | 6.4% above |
CNA has the edge over MS on trend strength, trading above more of its moving averages.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
CNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.5 | $38.6 | -13% |
| 2021 | $38.6 | $43.8 | +13% |
| 2022 | $43.8 | $41.9 | -4.4% |
| 2023 | $41.9 | $42.3 | +1.1% |
| 2024 | $42.3 | $48.4 | +14% |
| 2025 | $48.4 | $47.8 | -1.3% |
| 2026 YTD | $47.8 | $48.3 | +1.1% |
CNA has finished lower in three of the last six years. It's up 1.1% so far in 2026.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has the edge over CNA on returns for 2026, with the stronger performance.